Effects of chloromethylisothiazolinone/methylisothiazolinone (CMIT/MIT) on Th2/Th17-related immune modulation in an atopic dermatitis mouse model

Go, Han-Na; Lee, Seung Hwa; Cho, Hyun-Ju; Ahn, Jun-Woo; Kang, Mi‐Jin; Lee, So‐Yeon; Hong, Soo‐Jong

doi:10.1038/s41598-020-60966-8

Cited by 15 publications

(12 citation statements)

References 61 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Topical treatment with APR-ME on the inflamed area significantly reduced the expression of these cytokines. The role of IL-8, IL-17A and TNFα in skin inflammation has been widely described in previous studies [ 67 , 68 , 69 ]. TNF-α is a multifunctional agent that stimulates the acute phase of an inflammatory reaction and is secreted by different cell types, including monocytes, macrophages, Langerhans cells and microglia [ 70 , 71 ].…”

Section: Discussionmentioning

confidence: 99%

Apremilast Microemulsion as Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation

et al. 2020

View full text Add to dashboard Cite

Apremilast (APR) is a selective phosphodiesterase 4 inhibitor administered orally in the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis. The low solubility and permeability of this drug hinder its dermal administration. The purpose of this study was to design and characterize an apremilast-loaded microemulsion (APR-ME) as topical therapy for local skin inflammation. Its composition was determined using pseudo-ternary diagrams. Physical, chemical and biopharmaceutical characterization were performed. Stability of this formulation was studied for 90 days. Tolerability of APR-ME was evaluated in healthy volunteers while its anti-inflammatory potential was studied using in vitro and in vivo models. A homogeneous formulation with Newtonian behavior and droplets of nanometric size and spherical shape was obtained. APR-ME released the incorporated drug following a first-order kinetic and facilitated drug retention into the skin, ensuring a local effect. Anti-inflammatory potential was observed for its ability to decrease the production of IL-6 and IL-8 in the in vitro model. This effect was confirmed in the in vivo model histologically by reduction in infiltration of inflammatory cells and immunologically by decrease of inflammatory cytokines IL-8, IL-17A and TNFα. Consequently, these results suggest that this formulation could be used as an attractive topical treatment for skin inflammation.

show abstract

Section: Discussionmentioning

confidence: 99%

Apremilast Microemulsion as Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Thus, among the models evaluated for this study, six murine models demonstrated broad upregulation of Th1, Th2, Th17, and Th22 inflammation: Adam17 fl/fl Sox9 Cre , IL-23-exposed, OXA-induced, OVA-induced, ft, and vitamin D3-induced mice. OVA with CMIT/MIT exposure, ft mice, and HDM-induced mice [28,[36][37][38]. While ovalbumin commonly to induce eczema in mice, Go et al (2020), found that mice sensitized with CMIT/MIT before OVA displayed an augmented Th17 reaction than mice exposed to OVA alone [36].…”

Section: An Overview Of Mouse Models For Atopic Dermatitismentioning

confidence: 99%

Translational Relevance of Mouse Models of Atopic Dermatitis

Choi

Sutaria

Roh

et al. 2021

JCM

View full text Add to dashboard Cite

The complexity of atopic dermatitis (AD) continues to present a challenge in the appropriate selection of a mouse model because no single murine model completely recapitulates all aspects of human AD. This has been further complicated by recent evidence of the distinct AD endotypes that are dictated by unique patterns of inflammation involving Th1, Th2, Th17, and Th22 axes. A review of currently used mouse models demonstrates that while all AD mouse models consistently exhibit Th2 inflammation, only some demonstrate concomitant Th17 and/or Th22 induction. As the current understanding of the pathogenic contributions of these unique endotypes and their potential therapeutic roles expands, ongoing efforts to maximize a given mouse model’s homology with human AD necessitates a close evaluation of its distinct immunological signature.

show abstract

“…It was found that Thl7 and Tregs cells were also significantly related to the pathogenesis of asthma [51][52][53]. Synergy of multiple pathways, such as Th2, Th17, and even eosinophil/neutrophil infiltration, has been found in some asthma models [54][55][56]. The view that eosinophilic asthma is an exclusive TH2 disorder and neutrophil asthma is an exclusive TH17 disorder may be oversimplified [57].…”

Section: Adjusting Thl7/tregs Balancementioning

confidence: 99%

The Protective Effects of Helicobacter pylori Infection on Allergic Asthma

Zuo¹,

Yue²,

Sun³

et al. 2020

Int Arch Allergy Immunol

View full text Add to dashboard Cite

As an ancient Gram-negative bacterium, Helicobacter pylori has settled in human stomach. Eradicating H. pylori increases the morbidities of asthma and other allergic diseases. Therefore, H. pylori might play a protective role against asthma. The “disappearing microbiota” hypothesis suggests that the absence of certain types of the ancestral microbiota could change the development of immunology, metabolism, and cognitive ability in our early life, contributing to the development of some diseases. And the Hygiene Hypothesis links early environmental and microbial exposure to the prevalence of atopic allergies and asthma. Exposure to the environment and microbes can influence the growing immune system and protect subsequent immune-mediated diseases. H. pylori can inhibit allergic asthma by regulating the ratio of helper T cells 1/2 (Th1/Th2), Th17/regulatory T cells (Tregs), etc. H. pylori can also target dendritic cells to promote immune tolerance and enhance the protective effect on allergic asthma, and this effect relies on highly suppressed Tregs. The remote regulation of lung immune function by H. pylori is consistent with the gut-lung axis theory. Perhaps, H. pylori also protects against asthma by altering levels of stomach hormones, affecting the autonomic nervous system and lowering the expression of heat shock protein 70. Therapeutic products from H. pylori may be used to prevent and treat asthma. This paper reviews the possible protective influence of H. pylori on allergic asthma and the possible application of H. pylori in treating asthma.

show abstract

Effects of chloromethylisothiazolinone/methylisothiazolinone (CMIT/MIT) on Th2/Th17-related immune modulation in an atopic dermatitis mouse model

Cited by 15 publications

References 61 publications

Apremilast Microemulsion as Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation

Apremilast Microemulsion as Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation

Translational Relevance of Mouse Models of Atopic Dermatitis

The Protective Effects of <b><i>Helicobacter pylori</i></b> Infection on Allergic Asthma

Contact Info

Product

Resources

About